Key Documents
Curriculum Vitae available Online
David Feldman
- Emeritus (Active) Professor, Medicine - Endocrinology/Gerontology/Metab
- Member, Cancer Center
Contact Information
- Clinical Offices
826 Allardice Way Stanford, CA 94305 Telephone Work Fax
Web Site Links
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Consulting: Elsevier, Receptor Therapeutics, BioXell
Research Interests
Steroid hormones act by binding to intracellular receptors which regulate the expression of specific genes in target cells. My group is studying a number of aspects that relate molecular and cellular events of hormone action at the receptor level to clinically relevant questions. Some of the current projects are as follows:
1. Elucidation of the molecular basis of hereditary vitamin D resistant rickets, a genetic disease due to mutations in the vitamin D receptor.
2. Analysis of the endocrinologic mechanisms regulating vitamin D receptor expression and thereby modulating target organ sensitivity to the actions of vitamin D and its analogs.
3. Investigation of the role of vitamin D as a differentiating and antiproliferative agent with the potential to affect malignant cells, specifically prostate cancer.
4. Study of genetic variations in the vitamin D receptor gene and inheritance of low bone mass in relation to the development of osteoporosis.
Clinical Trials
Publications
- Anticancer Res. 2009; (9): 3605-10
- Mol Genet Metab. 2009;
- Endocr Relat Cancer. 2009;
- Endocrinology. 2009; (11): 4950-7
- Endocrinology. 2009;
- Endocr Rev. 2009; (5): 417-37
- Prostate. 2009; (7): 719-26
- Bone. 2009; (4): 743-6
- Int J Cancer. 2009; (9): 2050-9
- Endocrinology. 2009; (4): 1580-7
- Endocrinology. 2009; (2): 679-86
- Int J Radiat Oncol Biol Phys. 2008; (3): 935-40
- Int J Cancer. 2008; (3): 558-66
- Nutr Rev. 2007; (8 Pt 2): S113-5
- Nutr Rev. 2007; (8 Pt 2): S121-3
- J Steroid Biochem Mol Biol. 2007; (3-5): 694-702
- J Nutr. 2007; (1 Suppl): 205S-210S
- Arch Biochem Biophys. 2007; (2): 285-92
- J Biol Chem. 2007; (35): 25231-9
- J Bone Miner Res. 2007; V74-80
- Anticancer Res. 2006 Jul-Aug; (4A): 2525-30
- Endocrinology. 2006; (10): 4599-607
- Mol Cancer Ther. 2006; (6): 1539-49
- Mol Cancer Ther. 2006; (8): 2078-85
- Urology. 2006; (5): 1001-6
- Cancer Res. 2006; (8): 4516-24
- Cancer Causes Control. 2006; (10): 1237-44
- Cancer Res. 2005; (17): 7917-25
- J Urol. 2005; (3): 872-6; discussion 876
- Mol Cell Endocrinol. 2005; (1-2): 49-61
- J Steroid Biochem Mol Biol. 2005; (1-2): 31-6
- J Bone Miner Res. 2005; (9): 1680-91
- Endocrinology. 2004; (11): 5106-14
- Cancer Epidemiol Biomarkers Prev. 2004; (8): 1325-30
- Mol Cell Endocrinol. 2004; (1-2): 67-74
- J Bone Miner Res. 2004; (6): 1018-24
- Prostate. 2004; (3): 243-51
- Mol Endocrinol. 2004; (5): 1109-19
- J Steroid Biochem Mol Biol. 2004; (4): 307-15
- J Steroid Biochem Mol Biol. 2004; (3): 131-41
- Cancer Epidemiol Biomarkers Prev. 2003; (1): 23-7
- Endocr Relat Cancer. 2003; (2): 131-40
- J Nutr. 2003; (7 Suppl): 2461S-2469S
- Breast Cancer Res Treat. 2003; (1): 49-62
- Recent Results Cancer Res. 2003; 205-21
- Recent Results Cancer Res. 2003; 349-52
- Endocr Dev. 2003; 175-99
- J Cell Biochem. 2003; (2): 363-71
- Mol Genet Metab. 2002; (4): 314-8
- Mol Endocrinol. 2002; (11): 2538-46
- J Urol. 2002; (4 Pt 1): 1583-8
- Endocrinology. 2002; (5): 1889-900
- Steroids. 2001 Mar-May; (3-5): 293-300
- Bone. 2001; (3): 319-26
- J Urol. 2001; (4): 1319-24
- Cancer Res. 2001; (7): 2852-6
- J Steroid Biochem Mol Biol. 2001; (1): 29-37
- Mol Genet Metab. 2001; (2): 138-48
- Urology. 2001; (2 Suppl 1): 123-6
- J Clin Endocrinol Metab. 2001; (8): 3568-73
- Nat Rev Cancer. 2001; (1): 34-45
- Mol Cell Endocrinol. 2000; (1-2): 133-43
- Clin Cancer Res. 2000; (8): 3371-9
- Endocrinology. 2000; (7): 2548-56
- Nat Med. 2000; (6): 703-6
- Am J Med. 1999; (3): 355-70
- Endocrinology. 1999; (5): 2071-6
- Biochem Biophys Res Commun. 1999; (3): 718-22
- J Urol. 1999; (6): 2192-9
- Am J Med. 1999; (6): 637-9
- Endocrinology. 1999; (3): 1205-12
- J Bone Miner Res. 1998; (11): 1691-9
- J Urol. 1998; (6): 2035-9; discussion 2039-40
- J Bone Miner Res. 1998; (2): 259-64
- Biochem Biophys Res Commun. 1998; (3): 467-73
- J Bone Miner Res. 1998; (1): 31-5
- Endocrinology. 1997; (1): 12-8
- J Clin Invest. 1997; (2): 297-304
- J Bone Miner Res. 1997; (2): 234-40
- Mol Endocrinol. 1997; (3): 366-78
- Endocrinology. 1997; (8): 3290-8
- Academic Press, Inc., San Diego. 1997;
- J Bone Miner Res. 1997; (7): 1043-8
- Prostate. 1996; (1): 20-9
- J Bone Miner Res. 1996; (12): 1850-5
- J Clin Endocrinol Metab. 1996; (7): 2564-9
- Endocrinology. 1995; (1): 20-6
- Adv Exp Med Biol. 1995; 53-63
- Endocrinology. 1995; (2): 705-12
- Microbiology. 1995; 2685-92
- Environ Health Perspect. 1995; 129-33
- Proc Natl Acad Sci U S A. 1994; (3): 922-6
- Endocrinology. 1994; (5): 2171-7
- Cancer Res. 1994; (3): 805-10
- J Clin Endocrinol Metab. 1994; (2): 313-6
- Eur J Endocrinol. 1994; (1): 67-73
- Endocrinology. 1993; (4): 1808-14
- Endocrinology. 1993; (6): 2279-86
- Proc Natl Acad Sci U S A. 1993; (5): 1902-6
- Endocrinology. 1993; (5): 1952-60
- Mol Endocrinol. 1992; (2): 198-206
- West J Med. 1992; (1): 64-5
- Gene. 1992; (1): 123-8
- Mol Endocrinol. 1991; (4): 605-12
- Anesth Analg. 1991; (2): 204-8
- J Bone Miner Res. 1991; (10): 1099-107
- Mol Cell Endocrinol. 1990; (3): C57-62
- J Clin Invest. 1990; (6): 2071-9
- J Biol Chem. 1989; (19): 11186-92
- Mol Cell Biochem. 1989; (2): 119-36
- Endocrinology. 1989; (4): 1965-72
- J Clin Endocrinol Metab. 1989; (2): 263-9
- J Clin Microbiol. 1988; (10): 2110-5
- J Bone Miner Res. 1987; (2): 151-9
- Endocrinology. 1977; (3): 619-28